Our ability to digitise the world around us now readily outstrips our ability to process the data we generate. 
Rob Baxter reports
Kevin McNulty, director of product marketing for life sciences at Intralinks, explores the technology behind secure collaboration within the life sciences industry
Gary Tyreman, CEO at Univa, reveals why users of open-source software crave the most support
Carlo Poloni, president of Esteco and Engineering Professor at University of Trieste, argues in favour of optimisation
Chemistry software will be split between expert tools for computational chemists and 3D desktop modelling tools to support the work of medicinal chemists, says Dr Martin Slater, director of consulting at Cresset
When it comes to buying a LIMS, theres a right way and a wrong way. Autoscribes founder and CEO, John Boother, explains
How do we tackle the problem of energy efficiency in HPC centres? Dr Giampietro Tecchiolli, Eurotech CTO, offers his thoughts
Multi-parameter optimisation (MPO) in drug discovery is an area thats had incredible uptake recently, says Matt Segall, Optibriums CEO. He explains why
An accelerator war is brewing on the horizon! Adaptive Computing CEO Rob Clyde casts his eyes over the field of battle
Self-service informatics solutions - are they really what theyre cracked up to be? Dr Stephen Gallagher, CEO at Dotmatics, shares his view
The automotive sector is undergoing a period of rapid and disruptive transformation from both a business and technical standpoint.
Estimates suggest that the global laboratory informatics market, valued at $2.6 billion in 2019, will witness CAGR of 7.5 per cent over the next five years, reaching $3.8 billion in 2024[1].
Modern drug discovery and development workflows incorporate a growing range of automated, high-throughput technologies that can generate data on a truly impressive scale.
‘This will be the life sciences century … because of personalised medicine, information technology, and knowledge on biological systems,’ said Fred Hassan, a partner of Warburg Pincus and former CEO of Schering-Plough.
With data rates increasing and more complex challenges arising in life sciences, Panasas’ Jim Donovan and Dale Brantly discuss the benefits of using HPC for these workloads
As the complexity of both HPC hardware and the challenges that scientists are trying to solve using HPC systems increases, ensuring a system is utilised efficiently is necessary to deliver a computing service with value for money and a high research output.
Architectural specialisation is one option to continue to improve performance beyond the limits imposed by the slow down in Moore’s Law.
As not only the HPC industry but the larger computing ecosystem tries to overcome the slowdown and eventual end of transistor scaling described by Moore’s Law, scientists and researchers are implementing programmes that will define the technologies and new materials needed to supplement, or repla
